Compared to or in combination with conventional treatments, immune checkpoint inhibitors (ICIs) such as PD-1/PD-L1- and CTLA-4-blocking antibodies have transformed the treatment paradigm for NSCLC and demonstrated a significant survival benefit in patients [1,2]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.